

1                   **IMMUNE RESPONSES OF WILD BIRDS TO EMERGING INFECTIOUS**  
2   **DISEASES**

3  
4   Molly Staley<sup>1</sup> and Camille Bonneaud<sup>2\*</sup>

5  
6     <sup>1</sup> Department of Biological Sciences, Auburn University, Auburn AL 36849, U.S.A. Email:  
7     [mms0020@tigermail.auburn.edu](mailto:mms0020@tigermail.auburn.edu)

8     <sup>2</sup> Centre for Ecology and Conservation, University of Exeter, Penryn TR10 9EF, Cornwall U.K.  
9     Email: [c.bonneaud@exeter.ac.uk](mailto:c.bonneaud@exeter.ac.uk)

10    \* corresponding author

11  
12    **Running title:** Avian immunity to emerging pathogens

13  
14    **Keywords:** avian influenza, evolution of resistance, inflammation, *Mycoplasma gallisepticum*,  
15    novel pathogen, West Nile Virus (WNV)

16  
17    **Type of article:** Review

18 **SUMMARY**

19 Over the past several decades, outbreaks of emerging infectious diseases (EIDs) in wild birds  
20 have attracted worldwide media attention, either because of their extreme virulence or because of  
21 alarming spillovers into agricultural animals or humans. The pathogens involved have been  
22 found to infect a variety of bird hosts ranging from relatively few species (e.g., *Trichomonas*  
23 *gallinae*) to hundreds of species (e.g., West Nile Virus). Here we review and contrast the  
24 immune responses that wild birds are able to mount against these novel pathogens. We discuss  
25 the extent to which these responses are associated with reduced clinical symptoms, pathogen  
26 load and mortality, or conversely, how they are sometimes linked to worsened pathology and  
27 reduced survival. We then investigate how immune responses to EIDs can evolve over time in  
28 response to pathogen-driven selection using the illustrative case study of the epizootic outbreak  
29 of *Mycoplasma gallisepticum* in wild North American house finches (*Haemorhous mexicanus*).  
30 We highlight the need for future work to take advantage of the substantial inter- and intra-  
31 specific variation in disease progression and outcome following infections with EID to elucidate  
32 the extent to which immune responses confer increased resistance through pathogen clearance or  
33 may instead heighten pathogenesis.

## 34 INTRODUCTION

35 The drastic impact that infectious diseases can have on their hosts is illustrated in humans by  
36 records of mortality rates resulting from outbreaks like the Spanish flu pandemic of 1918-20 (1),  
37 as well as more recently by evidence of the role of pathogens in shaping our genome (2, 3).  
38 Emerging and re-emerging infectious diseases (EIDs), which include novel diseases that have  
39 spread to a new host species or population and historical diseases which have rapidly increased  
40 in incidence (4), are particularly strong selection events (5). They can therefore pose significant  
41 threats to wild populations through loss of genetic diversity, population declines, and even  
42 localised extinctions of already endangered species (6, 7). Given that risks of disease  
43 (re)emergence are thought to be aggravated by anthropogenic factors, ranging from our intensive  
44 farming practices to the increased movement of organisms across the globe (8), it is now urgent  
45 to improve our understanding of how hosts respond to novel diseases and how immune processes  
46 evolve subsequently.

47  
48 Over the past century, wild birds have been subject to devastating, yet well-documented, wildlife  
49 epizootics (Box 1) (9-14), making them valuable models for studying host immune responses to  
50 EIDs, as well as how pathogen-driven selection shapes the evolution of host immunity. For  
51 example, between December 2002 and January 2003, Hong Kong saw large die-offs of new and  
52 old world species of ducks, geese, and swans from Highly Pathogenic Avian Influenza (HPAI)  
53 (15), Great Britain lost over half a million greenfinches (*Carduelis chloris*) and chaffinches  
54 (*Fringilla coelebs*) within two years of the emergence of *Trichomonas gallinae* (13, 16), and an  
55 estimated hundreds of millions of house finches (*Haemorrhous mexicanus*) in the eastern United  
56 States died following the *Mycoplasma gallisepticum* epizootic that began in 1994 (9, 17, 18).

57 Similarly, the emergence of West Nile Virus (WNV) in New York (NY) in 1999 was  
58 accompanied by more than 17,000 dead bird sightings between May and November of that year,  
59 one-third of which were American crows (*Corvus brachyrhynchos*) (19). The causal role of  
60 disease in these observed mortality rates was confirmed through testing of carcasses and sick  
61 individuals (19, 20) followed by experimental infection studies (21-24). American crows  
62 experimentally infected with the NY-1999 WNV strain exhibited 100% mortality with severe  
63 clinical symptoms before death, including anorexia, weight loss, encephalitis, and oral and/or  
64 cloacal hemorrhaging (21, 22). Likewise, experimental infection with the H5N1 strain of HPAI  
65 resulted in 100% mortality of black swans (*Cygnus atratus*), mute swans (*Cygnus olor*),  
66 trumpeter swans (*Cygnus buccinator*), whooper swans (*Cygnus cygnus*) (23) and Canada geese  
67 (*Branta canadensis*) (24). Of these, some black swans died without ever exhibiting clinical  
68 symptoms, while the remaining black swans and mute swans died less than 24 hours after the  
69 onset of clinical symptoms that progressively worsened from mild listlessness to severe  
70 neurological symptoms including tremors and seizures (23). The severe impact that recent EID  
71 outbreaks have had on wild avian hosts therefore raises the question of these hosts' ability to  
72 mount immune responses to novel pathogens, as well as the extent to which immune responses  
73 may have allowed the host to fight off and/or clear the infection (25).

74

75 Despite the high mortality rates observed following these EID outbreaks, there appears to be  
76 marked variation in disease development and outcome among and within host species (22, 26).  
77 For example, between 2007-2010, wild-caught individuals from 27 of 53 bird species were found  
78 to be or to have been infected with *M. gallisepticum* based on PCR and/or testing of serum for  
79 antibodies via rapid plate agglutination, but only house finches (*Haemorhous mexicanus*),

80 American goldfinches (*Spinus tristis*), purple finches (*Haemorhous purpureus*) and black-capped  
81 chickadees (*Poecile atricapillus*) exhibited conjunctivitis (26). Experimental infections with NY-  
82 1999 WNV of 25 species of birds representing 17 orders also revealed inter-specific differences  
83 with mean peak viremias ranging from  $10^{2.8}$  to  $10^{12.1}$  PFU/ml, as well as highly variable  
84 mortality, even amongst species with the greatest viremias (22). In fact, in the same study,  
85 pathogen load did not necessarily predict disease outcome: although American crows had 100%  
86 mortality with a mean peak viremia of  $10^{10.2}$  PFU/ml, three other species, common grackles  
87 (*Quiscalus quiscula*), house sparrows (*Passer domesticus*), and blue jays (*Cyanocitta cristata*),  
88 reached higher mean viremias yet exhibited mortalities of only 33%, 50%, and 75%, respectively  
89 (22). Variation in disease progression and mortality is found not only among species but also  
90 within species, even in those species that display noticeably high mortality rates (27-30). For  
91 example, the emergence of *Plasmodium relictum* in the Hawaiian islands following the  
92 accidental introduction of its mosquito vector (*Culex quinquefasciatus*) in the early 20<sup>th</sup> century  
93 was devastating to populations of some native Hawaiian species, particularly Hawaiian  
94 honeycreepers such as the apapane (*Himatione sanguinea*), Hawaii amakihi (*Hemignathus*  
95 *virens*), and iiwi (*Vestiaria coccinea*) (14, 31). Yet experimental exposure of those species to *P.*  
96 *relictum* revealed that some individuals survived and those that did displayed lower levels of  
97 infected circulating erythrocytes and lost less mass than birds that died from the infection (28-  
98 30). Despite clear evidence of inter- and intra-specific variation in susceptibility to EIDs, our  
99 understanding of the precise immune mechanisms by which this variation is achieved remains  
100 incomplete.

101

102 Here we review the immune responses that are mounted by wild birds to EIDs using data  
103 garnered from field studies of live birds and carcasses, as well as laboratory-conducted  
104 experimental infections. First, we examine the types of immune responses wild birds are able to  
105 mount against novel pathogens at the cellular and molecular level, as well as evaluate how inter-  
106 and intra-specific variation in immunity can be linked to variation in disease severity and  
107 outcome. Examining such variation is essential for identifying the immune processes associated  
108 with differences in disease development and outcome as well as predicting whether and how  
109 these immune responses may evolve over time. Finally, we build on the well-documented  
110 epizootic outbreak of *Mycoplasma gallisepticum* in North American house finches to illustrate  
111 how immune responses can evolve in natural avian populations in response to novel diseases.

112

## 113 **IMMUNE RESPONSES OF WILD BIRDS TO EIDS**

114

115 Evidence from both field and laboratory studies indicate that some individuals are able to mount  
116 immune responses against EIDs and that these responses may confer long term protection against  
117 secondary exposures. For example, experimental infections of American kestrels (*Falco*  
118 *sparverius*) and dunlin (*Calidris alpina*) with H5N1 HPAI revealed that birds seroconverted and  
119 produced detectable levels of specific antibodies by 4 to 5 days post-infection (dpi) (32, 33).  
120 Similarly, experimental infection of laughing gulls (*Leucophaeus atricilla*) with H5N1 HPAI  
121 revealed that the 2 out of 6 individuals that survived infection produced antibodies against HPAI  
122 (27). In addition, these two surviving individuals had no gross lesions at necropsy and only mild  
123 encephalitis and pancreatitis due to lymphocytic and heterophilic infiltration, respectively. In  
124 contrast, laughing gulls following infection displayed more severe pathology including

125 widespread petechial hemorrhaging, necrotizing pancreatitis, cerebral neuronal necrosis, and  
126 necrotizing adrenalitis (27). This suggests that the humoral response mounted by the two  
127 surviving laughing gulls is likely to have enabled them to limit or even clear the infection. Such  
128 production of specific antibodies has been found to persist, giving rise to stronger adaptive  
129 immune responses upon re-infection. For instance, wild-caught rock pigeons (*Columba livia*)  
130 that had been naturally infected with WNV produced antibodies against the virus for at least 15  
131 months after capture (34). Similarly, WNV antibodies have been shown to persist in fish crows  
132 (*Corvus ossifragus*) for at least 12 months (35) and in various raptors for at least four years (36),  
133 while house sparrows experimentally infected with WNV had detectable antibodies for up to 36  
134 months (37). When re-challenged with WNV at 6, 12, 24, or 36 months post-infection, 52 of 71  
135 house sparrows exhibited  $\geq$  4-fold increases in antibody titers and only one individual re-  
136 challenged at 12 months post-infection became viremic; all individuals given a primary  
137 challenge, in contrast, became viremic (37). In the same way, house finches experimentally re-  
138 infected with *M. gallisepticum* 219, 314, or 425 days after the primary infection showed reduced  
139 conjunctival swelling and duration of clinical symptoms from day 7 dpi onwards relative the  
140 response they exhibited upon primary exposure (38).

141

142 Differences in the intensity and duration of humoral immune responses to EID may also be  
143 associated with variation in disease progression and outcome between avian host species.  
144 Experimental infections of American crows and fish crows with WNV revealed that fish crows  
145 showed milder and delayed clinical symptoms and lower pathogen loads, and exhibited peak  
146 viremias of  $10^{4.7-6.3}$  PFU/ml at 3-4 dpi that declined to  $10^{1.7-2.2}$  PFU/ml by 6 dpi, whereas  
147 American crows had peak viremias of  $10^{8.22-9.6}$  at 4-5 dpi that were still high ( $10^{7.3-7.7}$ ) at 6

148 dpi (39). Individuals from both species seroconverted at 5 dpi, but fish crows displayed a greater  
149 antibody production that went from 87-90% WNV serum neutralizing activity at 5 dpi to 93-  
150 100% at 6 dpi, while antibody production was lower in American crows with only 41-69% WNV  
151 neutralizing activity at 5 dpi and 69-79% at 6 dpi (39). Taken together, these results suggest that  
152 the stronger antibody response of fish crows to WNV may explain their increased ability to resist  
153 WNV infection relative to American crows (Figure 1). Whether this is truly the case is unclear,  
154 and explicit links between the intensity of humoral immune responses to EIDs, variation in  
155 pathogen load, disease development and outcome remain to be explored further.

156

157 The immune responses of wild birds to EIDs do not, however, necessarily give rise to decreased  
158 disease severity and a greater ability to clear infection, but may instead be associated with a  
159 worsening of clinical symptoms through immunopathology (for example see (40, 41)). This may  
160 be particularly true when infections trigger the activation of an inflammatory response, which  
161 can damage host tissue and mediate pathogenesis (42, 43). Damage from inflammation was, for  
162 e.g., found in HPAI-infected wood ducks (*Aix sponsa*) and laughing gulls that exhibited air  
163 sacculitis due to heterophil, lymphocyte, and plasma cell infiltration (27). Geese and swans also  
164 displayed mild to moderate heterophilic and lymphoplasmacytic inflammation in locations where  
165 HPAI antigen was detected (23). HPAI-infected tufted ducks (*Aythya fuligula*) exhibited  
166 encephalitis symptoms that upon necropsy were attributed to gliosis, neuronophagia, and  
167 inflammatory lesions associated with macrophage and lymphocyte infiltration (40). Furthermore,  
168 heterophilic infiltration was observed throughout the respiratory system of these individuals, yet  
169 there was no inflammation associated with the virus in the intestines (40). Patterns of  
170 inflammatory responses associated with sites of EID antigen localization have been observed



171 following both WNV and *T. gallinae* infections (16, 41, 44, 45). For instance, in response to  
172 WNV, both blue jays and American crows displayed mixed inflammatory reactions and spleen  
173 congestion due to inflammatory cell aggregates and fibrin deposition in areas of inflammation  
174 (44). Inflammation in wild finches that succumbed to *T. gallinae* infections in Canada (purple  
175 finches) and Great Britain (greenfinches and chaffinches) was found to result from mixed  
176 responses of heterophils, macrophages, and lymphocytes (16, 41). Such inflammatory responses  
177 were also responsible for the mucosal thickening seen in *T. gallinae*-infected greenfinches and  
178 chaffinches in Fennoscandia (45). Finally, post-mortem examination of wild birds naturally  
179 infected with H5N1 revealed variation in the distribution and severity of the inflammation of the  
180 brain, with species exhibiting some of the highest mortality rates from infection (i.e., swans and  
181 geese) also displaying the most severe encephalitis, while other species typically showed only  
182 mild to moderate encephalitis (Figure 2) (23, 27, 46-48). All these examples suggest that, in  
183 some cases, immune responses (i.e., inflammation) may be detrimental to the host and  
184 mediate/accelerate disease progression and outcome. Further support for such a hypothesis  
185 comes from the fact that pathogens have been found to benefit from activating inflammatory  
186 responses, for e.g., when inflammation disrupts host tissues and facilitates the infiltration and  
187 spread of the pathogen (49). Such damages incurred as a result of immune responsiveness are  
188 expected to have important consequences for the evolution of immunity to EIDs, with  
189 individuals that remain non-responsive or activate other components of the immune system being  
190 favoured over time.

191

192 While our understanding of the immune responses to EIDs in wild birds mainly consists of  
193 measures of antibody production or inflammation, investigations into the transcriptomic changes

194 following controlled experimental infection reveal a more complex picture. Huang and  
195 colleagues recently compared the global gene expression profiles of lungs from mallards (*Anas*  
196 *platyrhynchos*) infected with H5N1 HPAI to control individuals at 1, 2, and 3 dpi (50). The  
197 number of differentially expressed genes ranged from 2,257 to 3,066, depending on the day of  
198 measurement post-infection and analysis of these genes revealed complex expression patterns of  
199 genes known to play roles in immunity. For example, H5N1-infected ducks showed a marked  
200 increase (between 2 and 1,414-fold) in the expression of five interferon (IFN), 10 chemokine,  
201 and 10 interleukin (IL) or IL-receptor genes. The expression of genes known to be involved in  
202 the mammalian response to avian influenza and thought to be involved in the avian response  
203 including *DDX58*, *IFITM3* and *IFIT1–IFIT3*, increased between 6.9 and 440-fold, peaking at 2  
204 dpi (50). Additionally, mallards exhibited increased expression of two RNA helicases, IFN-  
205 induced proteins, toll-like receptors (TLRs), and major histocompatibility complex (MHC)  
206 genes. In contrast, other genes, including immunoglobulin M (IgM), three T-cell receptor (TCR)  
207 genes, and 4 CD molecule-encoding genes were shown to have decreased expression (50). Taken  
208 together, these data suggest EIDs elicit altered expression of multiple immune pathways in  
209 infected avian hosts.

210

211 Such a hypothesis of multiple immune pathways being involved in the responses of wild birds to  
212 EIDs is further supported by analyses of H5N1 HPAI-infected jungle crow (*Corvus*  
213 *macrorhynchos*) lung transcriptomes at 6 dpi, which revealed significant differential expression  
214 of 2,297 genes between infected and control individuals. Based on gene ontology analysis, the  
215 majority of differentially expressed genes were found to have immune-associated functions, with  
216 other affected genes being involved in cellular metabolism, transcriptional and translational

217 regulation, apoptosis, and phagocytosis (51). Vijayakumar and colleagues (51) expanded on  
218 these findings by using Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway analysis  
219 to refine the specific crow immunological pathways affected by HPAI infection (Figure 3). For  
220 instance, crows showed altered expression of multiple innate immune signalling pathways that  
221 are involved in viral recognition and influence activation of adaptive responses such as rig-1-like  
222 receptor (RLR) and Nod-like receptor (NLR) signalling pathways. Furthermore, infected crows  
223 demonstrated altered expression of genes involved in inflammation including cytokines and  
224 chemokines as well as adaptive immunity including TCR signalling (51). While gene expression  
225 analyses such as those obtained from HPAI-infected mallards and crows represent important  
226 advances in our understanding of the immune responses of wild birds to EIDs, they also  
227 highlight the complexity of these responses and the gaps in our understanding of the extent to  
228 which these responses allow the host to fight and/or clear infection.

229

## 230 **EVOLUTION OF AVIAN IMMUNITY TO EIDS: A CASE STUDY OF THE** 231 **OUTBREAK OF *MYCOPLASMA GALLISEPTICUM* IN HOUSE FINCHES**

232

### 233 *Evolution of resistance*

234 Few novel EID outbreaks in natural populations are as well documented as the *Mycoplasma*  
235 *gallisepticum* epizootic in North American house finches (52-56). *M. gallisepticum*, an endemic  
236 bacterial pathogen of poultry, was first detected in house finches in Maryland in 1994 (17).  
237 Although this bacterium readily switches hosts between chickens (*Gallus gallus*) and turkeys  
238 (*Meleagris gallopavo*), a single lineage of poultry origin has since been confirmed to be  
239 responsible for the house finch outbreak (57) (58). In house finches, *M. gallisepticum* manifests

240 as an upper respiratory tract and eye (conjunctivitis) infection (59) that can lead to death, in part,  
241 through blindness-induced starvation and predation. Following reports of individuals with  
242 swollen eyes at birdfeeders, the Cornell Laboratory of Ornithology set up a Citizen Science  
243 program (<http://www.birds.cornell.edu/hofi/>), through which volunteer birdwatchers could report  
244 observations of diseased house finches (60). This allowed for thorough documentation of both  
245 temporal and spatial changes in disease prevalence over time (61). Within 4 years, *M.*  
246 *gallisepticum* had spread throughout house finch populations in the eastern United States, killing  
247 an estimated tens of millions of house finches (9, 62). Prevalence, however, subsequently  
248 declined from epizootic to apparent enzootic levels (54, 61), raising important questions  
249 regarding the possible evolution of resistance/tolerance in house finches and underlying changes  
250 in host immune processes.

251

252 Investigations of host immune responses at epizootic onset, as well as how these responses  
253 subsequently evolved, is made possible in this system due to the persistence of unexposed house  
254 finch populations with which to compare infected populations (63). In 2007, Bonneaud et al. (63)  
255 experimentally infected wild-caught finches from disease-unexposed, western US (Arizona)  
256 populations and from disease-exposed, eastern US (Alabama) populations with *M. gallisepticum*  
257 to test whether resistance had spread in eastern house finch populations. After verification that  
258 the finches had never been naturally infected with *M. gallisepticum*, finches were either  
259 inoculated with a contemporary 2007-Alabama strain or sham-inoculated (controls). Two weeks  
260 post-infection, finches from disease-unexposed populations harboured nearly 50% greater  
261 bacterial loads than finches from exposed populations (Figure 4). Comparison of splenic  
262 transcriptional responses to infection of finches from unexposed versus exposed populations

263 measured before and after the apparent spread of host resistance, confirmed that disease-exposed  
264 house finch populations had evolved resistance to *M. gallisepticum* from standing genetic  
265 variation in only 12 years of disease exposure (63).

266

### 267 *Insights from studies in poultry*

268 *M. gallisepticum* is an economically-important bacterium known to infect a wide range of hosts  
269 of agricultural relevance (64), primarily chickens and turkeys. As a result, studies conducted in  
270 poultry have provided important insights into the pathogenesis of *M. gallisepticum*, as well as  
271 into the immune processes activated in the poultry host. These, in turn, improve our  
272 understanding of the host and pathogen processes taking place in the house finch host. As with  
273 other Mycoplasmas (65, 66), *M. gallisepticum* displays the ability to evade and manipulate the  
274 immune system of its hosts, with both potentiating and suppressive effects on various  
275 components of immunity (67). Teasing apart the immune processes under host and pathogen  
276 control and their role in resolving or benefiting infection, is therefore challenging. However,  
277 insights into bacterial-driven processes can be obtained, for e.g., by comparing the immune  
278 responses elicited in poultry by closely related virulent and attenuated strains of *M. gallisepticum*  
279 (68).

280

281 The establishment of infection (i.e., colonisation) by *M. gallisepticum* encompasses both  
282 adherence to host tissues and initial multiplication and occurs at the mucosal surface of the  
283 respiratory epithelium. This is made difficult by the presence of mucus and mucociliary  
284 clearance (69). Thus, to facilitate invasion, *M. gallisepticum* can use specific  
285 lipoproteins/lipopeptides that bind to host epithelial cells (66) and can induce a misdirected

286 inflammatory response that will disrupt the epithelial membrane (70, 71). Lesions in host tissues  
287 have been shown to result from the recruitment, activation and proliferation of heterophils and  
288 macrophages initially, and of lymphocytes subsequently, to and at the site of infection (72).  
289 Inoculations of chickens with virulent ( $R_{low}$ ) and attenuated (GT5) strains revealed that this  
290 leucocyte chemotaxis is achieved through the release of chemokines by infected tissues (68),  
291 including lymphotactin, CXCL13, CXCL14, RANTES, and macrophage inflammatory protein  $\beta$   
292 1(MIP-1 $\beta$ ) (68). MIP-1 $\beta$  secretion by chicken monocytes and macrophage-like cells was also  
293 confirmed *in vitro* (73) and shown to act as an attractant for many leucocytes, including  
294 heterophils, T lymphocytes and NK cells (73, 74). Such findings are consistent with the  
295 infiltration of non-specific CD8<sup>+</sup>TCR0 cells (most likely NK cells) in the tracheal mucosa of  
296 infected chickens, with infiltration peaking 1 week post-infection and thought to play an  
297 important role in disease progression through cytotoxicity (71, 72). Comparison of tracheal  
298 expression patterns following infection with  $R_{low}$  and GT5 also confirmed that chickens up-  
299 regulated pro-inflammatory cytokines (68), such as TNF- $\alpha$  and IL-6, which are responsible for  
300 local and systemic inflammation and can also give rise to tissue destruction and local necrosis.  
301 While the induction of an inflammatory response may therefore be beneficial to *M. gallisepticum*  
302 and facilitate invasion of the host (49, 75), persistence of infection may on the other hand  
303 necessitate the suppression of other components of immunity (71). Accordingly, chickens  
304 infected with  $R_{low}$  down-regulated the tracheal expression of the chemokine CCL20 and  
305 cytokines IL-8, IL-1 $\beta$  and IL-12p40 as early as 1 day post-inoculation (68). The fact that these  
306 cytokines are also involved in key inflammatory processes (76) highlights the complexity of  
307 pathogen-mediated manipulation of the host immune system. Furthermore, chickens infected  
308 with *M. gallisepticum* displayed lower T-cell activity 2 weeks post-infection (70, 72) and lower

309 humoral responses against *Haemophilus gallinarum* (77) or against avian pneumovirus (78)  
310 when co-inoculated with *M. gallisepticum*. The ability of *M. gallisepticum* to limit humoral and  
311 T-cell responses may be crucial for disease progression, as both local antibody-mediated  
312 responses and natural killer and cytotoxic T-cell responses have been suggested to play a role in  
313 controlling infection in chickens (71).

314

### 315 *Immune processes in the house finch host*

316 Comparison of transcriptional changes in the spleen of infected house finches from disease-  
317 unexposed/susceptible and exposed/resistant populations revealed significant differences as early  
318 as three days post-infection (79), indicating that the evolution of resistance in exposed  
319 populations involved changes in innate immune processes. Two-weeks post-infection,  
320 susceptible finches from unexposed populations down-regulated immune-associated genes and,  
321 relative to infected finches from exposed populations, exhibited significantly lower levels of  
322 transcripts of the following genes (79): T-cell immunoglobulin and mucin domain containing 4  
323 (*tim4*), MHC-class II-associated invariant chain I1 (*cd74*), lectin galactoside-binding soluble-2  
324 (*lgals2*), programmed death ligand 1 (*pd-11*), TCR beta chain (*tcrb*), immunoglobulin J (*IgJ*),  
325 neutrophil cytosolic factor-4 (*ncf4*), immunoglobulin superfamily member 4A (*Igsf4A*) and  
326 parathymosin (*ptms*). The only exception was the complement factor-H (*hCG40889*) gene,  
327 whose expression was up-regulated in infected finches from unexposed populations. However,  
328 because hCG40889 is known to restrict activation of the complement cascade (80), the overall  
329 expression patterns detected suggest that particular components of the immune system were  
330 being suppressed in finches from unexposed populations. Infected finches from exposed  
331 populations, on the other hand, were able to up-regulate the expression of immune-associated

332 genes two-weeks post-infection (79). Three of the genes up-regulated were: TIM4, which is  
333 involved in the differentiation of naïve CD4+ T cells into Th2 cells and which plays a role in  
334 preventing autoimmunity by mediating the clearance of apoptotic (phosphatidylserine-  
335 expressing) antigen-specific T cells after infection (81); CD74, which plays a role during the  
336 assembly of MHC class II molecules (82); NCF4 which plays a role in phagocytosis-induced  
337 oxidant production in heterophils (83). Taken together, these finding suggests that finches from  
338 disease-exposed populations have evolved the ability to resist pathogen-induced immuno-  
339 suppression and supports a role of both innate (e.g., phagocytosis by heterophils) and acquired  
340 (e.g., T-cell activity) immune processes in mediating resistance to pathogen spread (79).

341

342 Protective immunity is expected to evolve only when the costs of resisting infection are lower  
343 than those incurred by the infection itself (84, 85). Surprisingly, resistance to *M. gallisepticum*  
344 was found to have evolved despite the fact that the short-term energetic costs of immunity were  
345 greater than those of pathogenesis (86). Disentangling the costs attributable to immune  
346 functioning from those incurred from the parasite's presence is challenging in *in vivo* infection  
347 studies involving real pathogens (87). As a result, most of our understanding of the costs of  
348 immunity stems from studies using inert pathogens (88). However, two unusual features of the  
349 *M. gallisepticum*-house finch interaction permitted such a study in this system. First, it is  
350 possible to compare the response to infection between finches that are either susceptible or  
351 resistant depending on their population of origin (i.e., disease-unexposed or -exposed  
352 populations, respectively) (63, 89). Second, only resistant finches from disease-exposed  
353 populations are able to mount a protective immune response, as demonstrated both by the greater  
354 bacterial load and the overall down-regulation of immune-associated genes at early as 3 days



355 post-infection in finches from unexposed populations (63, 79). It is important to note, however,  
356 that genes associated with innate immunity, and in particular with inflammation, were not  
357 specifically examined in this study and hence may have been up-regulated in finches from  
358 unexposed populations at the start of the infection. This hypothesis is supported by the findings  
359 of Hawley and colleagues (90) showing increased levels of IL-6 in house finches 2 days post-  
360 inoculation with *M. gallisepticum*, as well as a 2°C increase in body temperature 1 day post-  
361 infection with a ~1°C increase persisting over the entire 2-weeks duration of the experimental  
362 infection. Regardless, the greater susceptibility of finches from disease-unexposed population  
363 implies that any potential inflammatory response was not protective and therefore likely reflects  
364 pathogenesis.

365  
366 As expected based on the findings above, infected finches from disease-exposed populations lost  
367 10 times more body mass over the course of two-weeks than uninfected controls from the same  
368 populations, revealing a cost of immunity (86) (Figure 5a). Furthermore, infected individuals  
369 from the disease-exposed population that lost the most mass and displayed immune-associated  
370 gene expression patterns in a direction consistent with greatest protective immunity (i.e.,  
371 resistance) against *M. gallisepticum*, also harboured the lowest pathogen loads in their  
372 conjunctivae (Figure 5b). Conversely, infected finches from disease-unexposed populations lost  
373 twice as much body mass as their controls, although this difference was marginal. In addition, in  
374 this population, infected individuals that lost the most mass harboured the greatest bacterial load  
375 in their conjunctivae, indicating a measurable cost of pathogenesis. Interestingly, the mass lost  
376 by infected birds differed significantly between populations, with mass loss being greater in  
377 infected finches from exposed populations (Figure 5). This indicates that counter to predictions,

378 the short-term energetic costs of immunity were greater than those of pathogenesis (86). These  
379 results therefore highlight the fact that resistance can evolve despite this, provided the fitness  
380 consequences of infection are sufficiently detrimental to the host.

381

### 382 *Evolution of tolerance*

383 The consequences of pathogen-driven selection on host evolution in this system are made all the  
384 more interesting by the fact that resistance was not the only host trait to evolve following  
385 epizootic outbreak. Adelman and colleagues (89) demonstrated that pathogen tolerance, which is  
386 the ability to limit the damage incurred from a given pathogen load (91), also spread in eastern  
387 house finch populations following disease exposure. To this end, they caught finches from  
388 unexposed western US (Arizona) and exposed eastern US (Alabama) populations in 2010 and  
389 experimentally infected them with an *M. gallisepticum* isolate collected in Virginia in 1994 (i.e.,  
390 at epizootic onset). Given that exposed populations were shown to have evolved resistance to *M.*  
391 *gallisepticum* between 2001 and 2007 (63), infection with an isolate sampled 16 years earlier  
392 ensured that any immunomodulatory effects of the bacteria would be minimised. Tolerance was  
393 then assessed using peak levels of pathology (i.e., eye lesions and mass loss) and bacterial load,  
394 as well as measures of pathology and bacterial load that incorporated infection duration and  
395 intensity (i.e., by measuring the area under the curves of pathology and pathogen load over time).  
396 Results showed that finches from the unexposed population had significantly greater peak eye  
397 lesions and mass loss than finches from the exposed population despite similar peak pathogen  
398 load. In addition, eye lesions also peaked a week later in finches from the exposed population  
399 relative to the unexposed one (89) (e.g., peak eye score; unexposed:  $4.13 \pm 0.48$  on day 7;  
400 exposed =  $5.79 \pm 0.14$  on day 14) (Figure 6).

401

402 The heightened tolerance of finches from the *M. gallisepticum*-exposed population was  
403 associated with a lower inflammatory response to infection relative to finches from the  
404 unexposed population (89). Specifically, finches from exposed populations displayed  
405 significantly lower levels of IL-1 $\beta$ , but marginally higher levels of IL-10, 24-hours post-infection  
406 (89) (Figure 7). IL-1 $\beta$  is a pro-inflammatory cytokine secreted by macrophages and that plays a  
407 key role in the acute phase response (76). The difference in the expression of IL-1 $\beta$  between  
408 finches from exposed and unexposed populations thus is likely to be responsible for the delayed  
409 and lowered febrile responses of the former (89) (increase in body temperature on day 1 post-  
410 infection; exposed: 0.71 $^{\circ}\pm$ 0.03 $^{\circ}$ C; unexposed:1.44 $^{\circ}\pm$ 0.18 $^{\circ}$ C).

411

412 While resistance and tolerance are often thought of as two alternative evolutionary responses to  
413 pathogen-driven selection (91, 92), studies on the house finch-*M. gallisepticum* system indicate  
414 that this may not necessarily be the case and that both processes can evolve in conjunction to  
415 reduce the overall fitness consequences of infection (63, 89). Interestingly, that tolerance reduced  
416 both inflammation and the severity of clinical symptoms (i.e., eye lesions and mass loss) without  
417 decreasing pathogen load (89) suggests that infection success is not necessarily positively  
418 correlated with the level of immunopathology suffered by the host. As a result, the extent to  
419 which host lesions can be minimised without impacting pathogen colonisation success or  
420 persistence will determine the relative contribution of resistance and tolerance to the  
421 evolutionary response of house finches to *M. gallisepticum*, with significant ramifications for the  
422 evolution of pathogen virulence (91).

423

424 **CONCLUSION**

425 Wild birds have been shown to mount immune responses to emerging infectious pathogens, but  
426 these responses are not always associated with reduced severity, or even absence, of clinical  
427 symptoms, nor do they necessarily allow the host to clear and survive the infection. The extent to  
428 which these immune responses help to fight novel pathogens, however, seems dependent on the  
429 type of response elicited, with humoral responses conferring some level of protection and  
430 inflammatory responses being associated with increased disease severity. The extent to which  
431 immune processes allow the host to fight the infection or, on the opposite, facilitate disease  
432 progression will have important consequences for the evolution of immune responses over time  
433 in response to pathogen-mediated selection. In cases where inflammation underlies disease  
434 pathology, a lack of immune responsiveness with or without the involvement of other  
435 components of immunity (e.g., humoral immunity) may be favoured by natural selection, thus  
436 leading to the evolution of tolerance and/or resistance. The combined spread of tolerance and  
437 resistance to EIDs appears to have occurred in house finches following the outbreak of the  
438 conjunctivitis-causing *M. gallisepticum*. Whether this evolutionary change was mediated solely  
439 by changes in the finches' inflammatory response, with important consequences for more  
440 pathogen-specific components of immunity (e.g., T cell and humoral immunity), or whether host  
441 evolution has occurred through parallel changes in multiple components of immunity (e.g.,  
442 inflammation and T cell immunity concurrently) remains to be determined. Finally, further  
443 insights into the role of different immune processes can be gained from detailed inter- and intra-  
444 specific comparisons linking immune responses to EIDs at a molecular and cellular level with  
445 variation in disease progression and outcome. By increasing our understanding of the role of host  
446 immune responses in EID outbreaks and persistence, studies conducted on wild bird populations

447 will have the potential to improve our predictions of species particularly at risk of infection by  
448 EIDs.

449

#### 450 **ACKNOWLEDGEMENTS**

451 We thank three anonymous reviewers for their insightful comments on a previous version of the  
452 manuscript. Staley and Bonneaud wrote the paper. Staley was supported by an Auburn  
453 University Cellular and Molecular Biosciences Peaks of Excellence Research Fellowship and  
454 Bonneaud by a Natural Environment Research Council grant (NE/M00256X).

455

#### 456 **REFERENCES**

- 457 1. Reid AH, Fanning TG, Janczewski TA and Taubenberger JK. Characterization of the  
458 1918 "Spanish" influenza virus neuraminidase gene. *Proceedings of the National*  
459 *Academy of Sciences of the United States of America* 2000; **97**: 6785-6790.
- 460 2. Fumagalli M, Sironi M, Pozzoli U, Ferrer-Admettla A, Pattini L and Nielsen R.  
461 Signatures of environmental genetic adaptation pinpoint pathogens as the main selective  
462 pressure through human evolution. *PLoS genetics* 2011; **7**: e1002355.  
463 doi:1002310.1001371/journal.pgen.1002355.
- 464 3. Karlsson EK, Kwiatkowski DP and Sabeti PC. Natural selection and infectious disease in  
465 human populations. *Nat Rev Genet* 2014; **15**: 379-393.
- 466 4. Morse SS. FACTORS IN THE EMERGENCE OF INFECTIOUS-DISEASES. *Emerging*  
467 *infectious diseases* 1995; **1**: 7-15.
- 468 5. Kerr PJ. Myxomatosis in Australia and Europe: A model for emerging infectious  
469 diseases. *Antiviral research* 2012; **93**: 387-415.

- 470 6. Daszak P, Cunningham AA and Hyatt AD. Wildlife ecology - Emerging infectious  
471 diseases of wildlife - Threats to biodiversity and human health. *Science* 2000; **287**: 443-  
472 449.
- 473 7. Lips KR, Brem F, Brenes R *et al.* Emerging infectious disease and the loss of biodiversity  
474 in a Neotropical amphibian community *Proceedings of the National Academy of Sciences*  
475 *of the United States of America* 2006; **103**: 3165-3170.
- 476 8. Patz JA, Daszak P, Tabor GM and al. e. Unhealthy landscapes: Policy recommendations  
477 on land use change and infectious disease emergence. *Environmental Health Perspectives*  
478 2004; **112**: 1092-1098.
- 479 9. Fischer JR, Stallknecht DE, Luttrell MP, Dhondt AA and Converse KA. Mycoplasmal  
480 conjunctivitis in wild songbirds: The spread of a new contagious disease in a mobile host  
481 population. *Emerging infectious diseases* 1997; **3**: 69-72.
- 482 10. Hayes EB, Komar N, Nasci RS, Montgomery SP, O'Leary DR and Campbell GL.  
483 Epidemiology and transmission dynamics of West Nile virus disease. *Emerging*  
484 *infectious diseases* 2005; **11**: 1167-1173.
- 485 11. Marra PP, Griffing S, Caffrey C *et al.* West Nile virus and wildlife. *Bioscience* 2004; **54**:  
486 393-402.
- 487 12. Olsen B, Munster VJ, Wallensten A, Waldenstrom J, Osterhaus AD and Fouchier RA.  
488 Global patterns of influenza a virus in wild birds. *Science* 2006; **312**: 384-388.
- 489 13. Lawson B, Robinson RA, Colvile KM *et al.* The emergence and spread of finch  
490 trichomonosis in the British Isles. *Philosophical transactions of the Royal Society of*  
491 *London Series B, Biological sciences* 2012; **367**: 2852-2863.

- 492 14. Warner RE. Role of Introduced Diseases in Extinction of Endemic Hawaiian Avifauna.  
493 *Condor* 1968; **70**: 101-&.
- 494 15. Ellis TM, Bousfield RB, Bissett LA *et al.* Investigation of outbreaks of highly pathogenic  
495 H5N1 avian influenza in waterfowl and wild birds in Hong Kong in late 2002. *Avian*  
496 *pathology : journal of the WVPA* 2004; **33**: 492-505.
- 497 16. Robinson RA, Lawson B, Toms MP *et al.* Emerging infectious disease leads to rapid  
498 population declines of common British birds. *PloS one* 2010; **5**: e12215.
- 499 17. Ley DH, Berkhoff JE and McLaren JM. Mycoplasma gallisepticum isolated from house  
500 finches (*Carpodacus mexicanus*) with conjunctivitis. *Avian diseases* 1996; **40**: 480-483.
- 501 18. Nolan PM, Hill GE and Stoehr AM. Sex, size, and plumage redness predict house finch  
502 survival in an epidemic. *P Roy Soc B-Biol Sci* 1998; **265**: 961-965.
- 503 19. Eidson M, Komar N, Sorhage F *et al.* Crow deaths as a sentinel surveillance system for  
504 West Nile virus in the northeastern United States, 1999. *Emerging infectious diseases*  
505 2001; **7**: 615-620.
- 506 20. Bernard KA, Maffei JG, Jones SA *et al.* West Nile virus infection in birds and  
507 mosquitoes, New York State, 2000. *Emerging infectious diseases* 2001; **7**: 679-685.
- 508 21. Brault AC, Langevin SA, Bowen RA *et al.* Differential virulence of West Nile strains for  
509 American crows. *Emerging infectious diseases* 2004; **10**: 2161-2168.
- 510 22. Komar N, Langevin S, Hinten S *et al.* Experimental infection of North American birds  
511 with the New York 1999 strain of West Nile virus. *Emerging infectious diseases* 2003; **9**:  
512 311-322.

- 513 23. Brown JD, Stallknecht DE and Swayne DE. Experimental infection of swans and geese  
514 with highly pathogenic avian influenza virus (H5N1) of Asian lineage. *Emerging*  
515 *infectious diseases* 2008; **14**: 136-142.
- 516 24. Pasick J, Berhane Y, Embury-Hyatt C *et al.* Susceptibility of Canada Geese (*Branta*  
517 *canadensis*) to highly pathogenic avian influenza virus (H5N1). *Emerging infectious*  
518 *diseases* 2007; **13**: 1821-1827.
- 519 25. Janeway C. *Immunobiology : the immune system in health and disease*. New York, NY,  
520 Garland Science, 2005.
- 521 26. Dhondt AA, DeCoste JC, Ley DH and Hochachka WM. Diverse wild bird host range of  
522 *Mycoplasma gallisepticum* in eastern North America. *PloS one* 2014; **9**: e103553.
- 523 27. Brown JD, Stallknecht DE, Beck JR, Suarez DL and Swayne DE. Susceptibility of North  
524 American ducks and gulls to H5N1 highly pathogenic avian influenza viruses. *Emerging*  
525 *infectious diseases* 2006; **12**: 1663-1670.
- 526 28. Atkinson CT, Woods KL, Dusek RJ, Sileo LS and Iko WM. Wildlife disease and  
527 conservation in Hawaii: pathogenicity of avian malaria (*Plasmodium relictum*) in  
528 experimentally infected iiwi (*Vestiaria coccinea*). *Parasitology* 1995; **111 Suppl**: S59-69.
- 529 29. Atkinson CT, Dusek RJ, Woods KL and Iko WM. Pathogenicity of avian malaria in  
530 experimentally-infected Hawaii Amakihi. *Journal of wildlife diseases* 2000; **36**: 197-204.
- 531 30. Yorinks N and Atkinson CT. Effects of malaria on activity budgets of experimentally  
532 infected juvenile Apapane (*Himatione sanguinea*). *Auk* 2000; **117**: 731-738.
- 533 31. Vanriper C, Vanriper SG, Goff ML and Laird M. The Epizootiology and Ecological  
534 Significance of Malaria in Hawaiian Land Birds. *Ecol Monogr* 1986; **56**: 327-344.



- 535 32. Hall JS, Franson JC, Gill RE *et al.* Experimental challenge and pathology of highly  
536 pathogenic avian influenza virus H5N1 in dunlin (*Calidris alpina*), an intercontinental  
537 migrant shorebird species. *Influenza and other respiratory viruses* 2011; **5**: 365-372.
- 538 33. Hall JS, Ip HS, Franson JC *et al.* Experimental infection of a North American raptor,  
539 American Kestrel (*Falco sparverius*), with highly pathogenic avian influenza virus  
540 (H5N1). *PloS one* 2009; **4**: e7555.
- 541 34. Gibbs SE, Hoffman DM, Stark LM *et al.* Persistence of antibodies to West Nile virus in  
542 naturally infected rock pigeons (*Columba livia*). *Clinical and diagnostic laboratory*  
543 *immunology* 2005; **12**: 665-667.
- 544 35. Wilcox BR, Yabsley MJ, Ellis AE, Stallknecht DE and Gibbs SE. West Nile virus  
545 antibody prevalence in American crows (*Corvus brachyrhynchos*) and fish crows (*Corvus*  
546 *ossifragus*) in Georgia, USA. *Avian diseases* 2007; **51**: 125-128.
- 547 36. Nemeth NM, Kratz GE, Bates R, Scherpelz JA, Bowen RA and Komar N. Naturally  
548 induced humoral immunity to West Nile virus infection in raptors. *EcoHealth* 2008; **5**:  
549 298-304.
- 550 37. Nemeth NM, Oesterle PT and Bowen RA. Humoral immunity to West Nile virus is long-  
551 lasting and protective in the house sparrow (*Passer domesticus*). *The American journal of*  
552 *tropical medicine and hygiene* 2009; **80**: 864-869.
- 553 38. Sydenstricker KV, Dhondt AA, Hawley DM, Jennelle CS, Kollias HW and Kollias GV.  
554 Characterization of experimental *Mycoplasma gallisepticum* infection in captive house  
555 finch flocks. *Avian diseases* 2006; **50**: 39-44.

- 556 39. Nemeth NM, Thomsen BV, Spraker TR *et al.* Clinical and pathologic responses of  
557 American crows (*Corvus brachyrhynchos*) and fish crows (*C. ossifragus*) to experimental  
558 West Nile virus infection. *Veterinary pathology* 2011; **48**: 1061-1074.
- 559 40. Brojer C, Agren EO, Uhlhorn H *et al.* Pathology of natural highly pathogenic avian  
560 influenza H5N1 infection in wild tufted ducks (*Aythya fuligula*). *Journal of veterinary*  
561 *diagnostic investigation : official publication of the American Association of Veterinary*  
562 *Laboratory Diagnosticians, Inc* 2009; **21**: 579-587.
- 563 41. Forzan MJ, Vanderstichel R, Melekhovets YF and McBurney S. Trichomoniasis in  
564 finches from the Canadian Maritime provinces--An emerging disease. *The Canadian*  
565 *veterinary journal La revue veterinaire canadienne* 2010; **51**: 391-396.
- 566 42. Graham AL, Allen JE and Read AF. Evolutionary causes and consequences of  
567 immunopathology. *Annu Rev Ecol Evol S* 2005; **36**: 373-397.
- 568 43. Rouse BT and Sehrawat S. Immunity and immunopathology to viruses: what decides the  
569 outcome? *Nature reviews Immunology* 2010; **10**: 514-526.
- 570 44. Weingartl HM, Neufeld JL, Capps J and Marszal P. Experimental West Nile virus  
571 infection in blue jays (*Cyanocitta cristata*) and crows (*Corvus brachyrhynchos*).  
572 *Veterinary pathology* 2004; **41**: 362-370.
- 573 45. Neimanis AS, Handeland K, Isomursu M *et al.* First report of epizootic trichomoniasis in  
574 wild finches (family Fringillidae) in southern Fennoscandia. *Avian diseases* 2010; **54**:  
575 136-141.
- 576 46. Brojer C, Agren EO, Uhlhorn H, Bernodt K, Jansson DS and Gavier-Widen D.  
577 Characterization of encephalitis in wild birds naturally infected by highly pathogenic  
578 avian influenza H5N1. *Avian diseases* 2012; **56**: 144-152.

- 579 47. Kwon YK, Thomas C and Swayne DE. Variability in pathobiology of South Korean  
580 H5N1 high-pathogenicity avian influenza virus infection for 5 species of migratory  
581 waterfowl. *Veterinary pathology* 2010; **47**: 495-506.
- 582 48. Keawcharoen J, van Riel D, van Amerongen G *et al.* Wild ducks as long-distance vectors  
583 of highly pathogenic avian influenza virus (H5N1). *Emerging infectious diseases* 2008;  
584 **14**: 600-607.
- 585 49. Hornef MW, Wick MJ, Rhen M and Normark S. Bacterial strategies for overcoming host  
586 innate and adaptive immune responses. *Nat Immunol* 2002; **3**: 1033-1040.
- 587 50. Huang Y, Li Y, Burt DW *et al.* The duck genome and transcriptome provide insight into  
588 an avian influenza virus reservoir species. *Nature genetics* 2013; **45**: 776-783.
- 589 51. Vijayakumar P, Mishra A, Ranaware PB *et al.* Analysis of the crow lung transcriptome in  
590 response to infection with Highly Pathogenic H5N1 Avian Influenza Virus. *Gene* 2015.
- 591 52. Dhondt AA, Badyaev AV, Dobson AP *et al.* Dynamics of mycoplasmal conjunctivitis in  
592 the native and introduced range of the host. *EcoHealth* 2006; **3**: 95-102.
- 593 53. Hartup BK, Dhondt AA, Sydenstricker KV, Hochachka WM and Kollias GV. Host range  
594 and dynamics-of mycoplasmal conjunctivitis among birds in North America. *Journal of*  
595 *wildlife diseases* 2001; **37**: 72-81.
- 596 54. Hochachka WM and Dhondt AA. Density-dependent decline of host abundance resulting  
597 from a new infectious disease. *Proceedings of the National Academy of Sciences of the*  
598 *United States of America* 2000; **97**: 5303-5306.
- 599 55. Farmer KL, Hill GE and Roberts SR. Susceptibility of wild songbirds to the house finch  
600 strain of *Mycoplasma gallisepticum*. *Journal of wildlife diseases* 2005; **41**: 317-325.

- 601 56. Roberts SR, Nolan PM, Lauerman LH, Li LQ and Hill GE. Characterization of the  
602 mycoplasmal conjunctivitis epizootic in a house finch population in the southeastern  
603 USA. *Journal of wildlife diseases* 2001; **37**: 82-88.
- 604 57. Delaney NF, Balenger S, Bonneaud C *et al.* Ultrafast Evolution and Loss of CRISPRs  
605 Following a Host Shift in a Novel Wildlife Pathogen, *Mycoplasma gallisepticum*. *Plos*  
606 *Genetics* 2012; **8**.
- 607 58. Hochachka WM, Dhondt AA, Dobson A, Hawley DM, Ley DH and Lovette IJ. Multiple  
608 host transfers, but only one successful lineage in a continent-spanning emergent  
609 pathogen. *Proc R Soc B-Biol Sci* 2013; **280**.
- 610 59. Ley DH, Berkhoff JE and McLaren JM. *Mycoplasma gallisepticum* isolated from house  
611 finches (*Carpodacus mexicanus*) with conjunctivitis. *Avian Diseases* 1996; **40**: 480-483.
- 612 60. Dhondt AA, Tessaglia DL and Slothower RL. Epidemic mycoplasmal conjunctivitis in  
613 house finches from Eastern North America. *Journal of wildlife diseases* 1998; **34**: 265-  
614 280.
- 615 61. Hartup BK, Bickal JM, Dhondt AA, Ley DH and Kollias GV. Dynamics of conjunctivitis  
616 and *Mycoplasma gallisepticum* infections in house finches. *Auk* 2001; **118**: 327-333.
- 617 62. Nolan PM, Hill GE and Stoehr AM. Sex, size, and plumage redness predict house finch  
618 survival in an epidemic. *Proc R Soc Lond Ser B-Biol Sci* 1998; **265**: 961-965.
- 619 63. Bonneaud C, Balenger S, Russell AF, Zhang J, Hill GE and Edwards SV. Rapid  
620 evolution of disease resistance is accompanied by functional changes in gene expression  
621 in a wild bird. *Proceedings of the National Academy of Sciences of the United States of*  
622 *America* 2011; **108**: 7866-7871.

- 623 64. Stipkovits L and Kempf I. Mycoplasmoses in poultry. *Rev Sci Tech Off Int Epizoot* 1996;  
624 **15**: 1495-1525.
- 625 65. Razin S, Yogev D and Naot Y. Molecular biology and pathogenicity of mycoplasmas.  
626 *Microbiol Mol Biol Rev* 1998; **62**: 1094-1156.
- 627 66. Chambaud I, Wroblewski H and Blanchard A. Interactions between mycoplasma  
628 lipoproteins and the host immune system. *Trends Microbiol* 1999; **7**: 493-499.
- 629 67. Browning GF and Citti C. *Mollicutes: molecular biology and pathogenesis*. Norfolk, UK,  
630 Caister Academic Press, 2014.
- 631 68. Mohammed J, Frasca S, Cecchini K *et al*. Chemokine and cytokine gene expression  
632 profiles in chickens inoculated with *Mycoplasma gallisepticum* strains R-low or GT5.  
633 *Vaccine* 2007; **25**: 8611-8621.
- 634 69. Jordan JL, Chang HY, Balish MF *et al*. Protein P200 is dispensable for *Mycoplasma*  
635 *pneumoniae* hemadsorption but not gliding motility or colonization of differentiated  
636 bronchial epithelium. *Infect Immun* 2007; **75**: 518-522.
- 637 70. Ganapathy K and Bradbury JM. Effects of cyclosporin A on the immune responses and  
638 pathogenesis of a virulent strain of *Mycoplasma gallisepticum* in chickens. *Avian Pathol*  
639 2003; **32**: 495-502.
- 640 71. Gaunson JE, Philip CJ, Whithear KG and Browning GF. The cellular immune response in  
641 the tracheal mucosa to *Mycoplasma gallisepticum* in vaccinated and unvaccinated  
642 chickens in the acute and chronic stages of disease. *Vaccine* 2006; **24**: 2627-2633.
- 643 72. Gaunson JE, Philip CJ, Whithear KG and Browning GF. Lymphocytic infiltration in the  
644 chicken trachea in response to *Mycoplasma gallisepticum* infection. *Microbiology-(UK)*  
645 2000; **146**: 1223-1229.

- 646 73. Lam KM and DaMassa AJ. Mycoplasma gallisepticum-induced release of macrophage  
647 inflammatory protein-1 beta from chicken monocytes-macrophages. *J Comp Pathol*  
648 2000; **122**: 35-42.
- 649 74. Menten P, Wuyts A and Van Damme J. Macrophage inflammatory protein-1. *Cytokine*  
650 *Growth Factor Rev* 2002; **13**: 455-481.
- 651 75. d'Hauteville H, Khan S, Maskell DJ *et al.* Two msbB genes encoding maximal acylation  
652 of lipid A are required for invasive *Shigella flexneri* to mediate inflammatory rupture and  
653 destruction of the intestinal epithelium. *J Immunol* 2002; **168**: 5240-5251.
- 654 76. Murphy KP. *Janeway's immunobiology*. New York, USA, Garland Science, 2012.
- 655 77. Matsuo K, Kuniyasu C, Yamada S, Susumi S and Yamamoto S. Suppression of immuno-  
656 responses to *Hemophilus gallinarum* with nonviable *Mycoplasma gallisepticum* in  
657 chickens. *Avian diseases* 1978; **22**: 552-561.
- 658 78. Naylor CJ, Alankari AR, Alafaleq AI, Bradbury JM and Jones RC. Exacerbation of  
659 Mycoplasma-Gallisepticum Infection in Turkeys by Rhinotracheitis Virus. *Avian Pathol*  
660 1992; **21**: 295-305.
- 661 79. Bonneaud C, Balenger SL, Zhang J, Edwards SV and Hill GE. Innate immunity and the  
662 evolution of resistance to an emerging infectious disease in a wild bird. *Molecular*  
663 *ecology* 2012; **21**: 2628-2639.
- 664 80. de Cordoba SR and de Jorge EG. Translational mini-review series on complement factor  
665 H: Genetics and disease associations of human complement factor H. *Clinical and*  
666 *Experimental Immunology* 2008; **151**: 1-13.
- 667 81. Kobayashi N, Karisola P, Pena-Cruz V *et al.* TIM-1 and TIM-4 glycoproteins bind  
668 phosphatidylserine and mediate uptake of apoptotic cells. *Immunity* 2007; **27**: 927-940.

- 669 82. Bertolino P and RoubourdinCombe C. The MHC class II-associated invariant chain: A  
670 molecule with multiple roles in MHC class II biosynthesis and antigen presentation to  
671 CD4(+) T cells. *Crit Rev Immunol* 1996; **16**: 359-379.
- 672 83. Matute JD, Arias AA, Wright NAM *et al.* A new genetic subgroup of chronic  
673 granulomatous disease with autosomal recessive mutations in p40(phox) and selective  
674 defects in neutrophil NADPH oxidase activity. *Blood* 2009; **114**: 3309-3315.
- 675 84. Boots M and Bowers RG. The evolution of resistance through costly acquired immunity.  
676 *Proc R Soc Lond Ser B-Biol Sci* 2004; **271**: 715-723.
- 677 85. Boots M and Haraguchi Y. The evolution of costly resistance in host-parasite systems.  
678 *Am Nat* 1999; **153**: 359-370.
- 679 86. Bonneaud C, Balenger SL, Hill GE and Russell AF. Experimental evidence for distinct  
680 costs of pathogenesis and immunity against a natural pathogen in a wild bird. *Molecular*  
681 *ecology* 2012; **21**: 4787-4796.
- 682 87. Owen JP, Nelson AC and Clayton DH. Ecological immunology of bird-ectoparasite  
683 systems. *Trends Parasitol* 2010; **26**: 530-539.
- 684 88. Bonneaud C, Mazuc J, Gonzalez G *et al.* Assessing the cost of mounting an immune  
685 response. *Am Nat* 2003; **161**: 367-379.
- 686 89. Adelman JS, Kirkpatrick L, Grodio JL and Hawley DM. House Finch Populations Differ  
687 in Early Inflammatory Signaling and Pathogen Tolerance at the Peak of *Mycoplasma*  
688 *gallisepticum* Infection. *Am Nat* 2013; **181**: 674-689.
- 689 90. Hawley DM, DuRant SE, Wilson AF, Adelman JS and Hopkins WA. Additive metabolic  
690 costs of thermoregulation and pathogen infection. *Funct Ecol* 2012; **26**: 701-710.

- 691 91. Raberg L, Graham AL and Read AF. Decomposing health: tolerance and resistance to  
692 parasites in animals. *Philos Trans R Soc B-Biol Sci* 2009; **364**: 37-49.
- 693 92. Raberg L, Sim D and Read AF. Disentangling genetic variation for resistance and  
694 tolerance to infectious diseases in animals. *Science* 2007; **318**: 812-814.
- 695 93. Woodworth BL, Atkinson CT, Lapointe DA *et al.* Host population persistence in the face  
696 of introduced vector-borne diseases: Hawaii amakihi and avian malaria. *Proceedings of*  
697 *the National Academy of Sciences of the United States of America* 2005; **102**: 1531-1536.
- 698 94. Foster JT, Woodworth BL, Eggert LE *et al.* Genetic structure and evolved malaria  
699 resistance in Hawaiian honeycreepers. *Molecular ecology* 2007; **16**: 4738-4746.
- 700 95. Atkinson CT, Saili KS, Utzurrum RB and Jarvi SI. Experimental evidence for evolved  
701 tolerance to avian malaria in a wild population of low elevation Hawai'i 'Amakihi  
702 (*Hemignathus virens*). *EcoHealth* 2013; **10**: 366-375.
- 703 96. Dhondt AA, Altizer S, Cooch EG *et al.* Dynamics of a novel pathogen in an avian host:  
704 Mycoplasmal conjunctivitis in house finches. *Acta tropica* 2005; **94**: 77-93.
- 705 97. Eidson M, Miller J, Kramer L, Cherry B, Hagiwara Y and West Nile Virus Bird  
706 Mortality Analysis G. Dead crow densities and human cases of West Nile virus, New  
707 York State, 2000. *Emerging infectious diseases* 2001; **7**: 662-664.
- 708 98. Bernard KA and Kramer LD. West Nile virus activity in the United States, 2001. *Viral*  
709 *immunology* 2001; **14**: 319-338.
- 710 99. Kramer LD and Bernard KA. West Nile virus infection in birds and mammals. *Annals of*  
711 *the New York Academy of Sciences* 2001; **951**: 84-93.



- 712 100. Lanciotti RS, Roehrig JT, Deubel V *et al.* Origin of the West Nile virus responsible for  
713 an outbreak of encephalitis in the northeastern United States. *Science* 1999; **286**: 2333-  
714 2337.
- 715 101. Kramer LD and Bernard KA. West Nile virus in the western hemisphere. *Current opinion*  
716 *in infectious diseases* 2001; **14**: 519-525.
- 717 102. Sturm-Ramirez KM, Ellis T, Bousfield B *et al.* Reemerging H5N1 influenza viruses in  
718 Hong Kong in 2002 are highly pathogenic to ducks. *Journal of virology* 2004; **78**: 4892-  
719 4901.
- 720 103. Chen H, Smith GJ, Zhang SY *et al.* Avian flu: H5N1 virus outbreak in migratory  
721 waterfowl. *Nature* 2005; **436**: 191-192.
- 722 104. Liu J, Xiao H, Lei F *et al.* Highly pathogenic H5N1 influenza virus infection in migratory  
723 birds. *Science* 2005; **309**: 1206.
- 724 105. Sakoda Y, Ito H, Uchida Y *et al.* Reintroduction of H5N1 highly pathogenic avian  
725 influenza virus by migratory water birds, causing poultry outbreaks in the 2010-2011  
726 winter season in Japan. *The Journal of general virology* 2012; **93**: 541-550.
- 727 106. Khan SU, Berman L, Haider N *et al.* Investigating a crow die-off in January-February  
728 2011 during the introduction of a new clade of highly pathogenic avian influenza virus  
729 H5N1 into Bangladesh. *Archives of virology* 2014; **159**: 509-518.
- 730 107. Weber S, Harder T, Starick E *et al.* Molecular analysis of highly pathogenic avian  
731 influenza virus of subtype H5N1 isolated from wild birds and mammals in northern  
732 Germany. *The Journal of general virology* 2007; **88**: 554-558.

- 733 108. Smietanka K, Fusaro A, Domanska-Blicharz K *et al.* Full-length genome sequencing of  
734 the Polish HPAI H5N1 viruses suggests separate introductions in 2006 and 2007. *Avian*  
735 *diseases* 2010; **54**: 335-339.
- 736 109. Chi JF, Lawson B, Durrant C *et al.* The finch epidemic strain of *Trichomonas gallinae* is  
737 predominant in British non-passerines. *Parasitology* 2013; **140**: 1234-1245.
- 738
- 739 |

740 **BOX 1:** The emerging infectious diseases (EIDs) of wild birds discussed in this review (ordered  
741 chronologically).

742

743 *Plasmodium relictum* – *P. relictum*, a protist responsible for causing avian malaria, is among the  
744 earliest documented EIDs known to significantly affect wild birds. Following the accidental  
745 introduction of its mosquito vector, *Culex quinquefasciatus*, to the Hawaiian islands in the early  
746 20<sup>th</sup> century, this novel disease devastated local populations of honeycreepers including the  
747 apapane (*Himatione sanguinea*), Hawaii amakihi (*Hemignathus virens*), and iiwi (*Vestiaria*  
748 *coccinea*) and contributed to the extinction of several others. As a result many native Hawaiian  
749 birds could only be found in large numbers in high elevation forests and islands that were free of  
750 mosquitos (14, 31). However, based on mist-netting surveys conducted on the island of Hawaii  
751 in 2002, Hawaii amakihi have persisted and increased in abundance at low elevations where *P.*  
752 *relictum* is prevalent, such that Hawaii amakihi are more abundant at low elevations than at high  
753 elevations (93). Furthermore, these populations have been shown to be genetically isolated from  
754 high elevation populations (94), creating a unique system in which the evolution of host  
755 immunity to EIDs can be examined (95).

756

757 *Mycoplasma gallisepticum* – In 1994, the poultry pathogen *M. gallisepticum* was found to be the  
758 causative agent of a novel conjunctivitis disease observed in house finches (*Haemorhous*  
759 *mexicanus*) in Maryland, United States. Within 3-4 years this bacterial pathogen spread  
760 throughout the entire eastern range of the house finch in North America killing an estimated tens  
761 of millions of house finches. These deaths resulted in part from the manifestation of *M.*

762 *gallisepticum* as a respiratory disease as well and in part from the conjunctivitis-induced  
763 blindness leading to starvation and increased susceptibility to predation (9, 17, 18, 61, 96).

764

765 **West Nile Virus** - In 1999, a novel highly pathogenic strain of West Nile Virus was found to be  
766 responsible for the unusually high numbers of bird deaths in New York (NY), United States (19,  
767 97-99). While some affected birds displayed no symptoms before death, the most affected  
768 species such as American crows (*Corvus brachyrhynchos*) displayed severe symptoms including  
769 anorexia, weakness, and mass loss as well as neurological problems such as ataxia, tremors,  
770 circling, disorientation, and impaired vision resulting from WNV-induced encephalitis (21).  
771 Sequence analysis of WNV isolates from this epidemic found NY-1999 WNV isolates to be most  
772 closely related to WNV isolated from a dead goose in Israel in 1998 (100). Combined with a lack  
773 of evidence for WNV in the United States before 1999, the epidemic was likely the result of a  
774 novel introduction of WNV to the US with a probable Mediterranean origin (99-101).

775

776 **Highly pathogenic avian influenza (HPAI) virus** – Historically waterfowl have been  
777 considered asymptomatic carriers of avian influenza viruses. However, H5N1 HPAI was found  
778 to be responsible for the deaths of new and old world species of ducks, geese, and swans in two  
779 Hong Kong parks between December 2002 and January 2003. Affected birds exhibited  
780 symptoms ranging from slight inactivity, inappetence, and ruffled feathers to severe  
781 neurological symptoms including paresis, paralysis, tremors, and unusual head tilt, with death  
782 often occurring within 24 hours of the onset of symptoms (15). Indeed, H5N1 isolates collected  
783 during the outbreak were found to cause systemic disease and similar severe clinical symptoms  
784 in mallards (*Anas platyrhynchos*) whereas 1997 and 2001 H5N1 isolates from Hong Kong did not

785 (102). Subsequent outbreaks of HPAI affecting waterfowl occurred in China (103, 104), Japan  
786 (105) Bangladesh (106) as well as numerous European countries in 2006 (107, 108).

787

788 ***Trichomonas gallinae*** – In 2005, a clonal strain of the protozoan *T. gallinae* spread from wild  
789 columbiform birds to chaffinches (*Fringilla coelebs*) and greenfinches (*Carduelis chloris*) in  
790 Great Britain, causing the loss of an estimated half a million birds by 2007 (16). While chaffinch  
791 populations began to stabilize, greenfinch populations further declined, with an estimated  
792 population decrease from 4.3 to 2.8 million, or overall 1.5 million, greenfinches by 2009 (13).  
793 Since then, *T. gallinae* has spread to finches in other European countries including Norway,  
794 Sweden, and Finland (45) and has been found to cause disease in raptors including  
795 sparrowhawks (*Accipiter nuscis*) and tawny owls (*Strix aluco*), presumably due to consumption of  
796 infected finches (109).

797

798 **FIGURE LEGENDS**

799

800 **Figure 1:** Using experimental WNV infections in American crows (*Corvus brachyrhynchos*) and  
801 fish crows (*Corvus ossifragus*), Nemeth and colleagues (39) show differences in disease  
802 progression and outcome between these two species that may be associated with differences in  
803 humoral immune responses. (Modified from (39))

804 **Figure 2:** Severity of H5N1 HPAI encephalitis in nine naturally infected wild bird species: mute  
805 swans (*Cygnus olor*), Canada geese (*Branta Canadensis*), greater scaup (*Aythya marila*),  
806 European eagle owls (*Bubo bubo*), tufted duck (*Aythya fuligula*), goosander (common  
807 merganser; *Mergus merganser*), common buzzard (*Buteo buteo*), smew (*Mergellus albellus*), and  
808 herring gull (*Larus argentatus*). Severity is based on use of immunohistochemistry to assess  
809 intensity and area of staining for the following: total area of inflammation, inflammatory  
810 components, viral antigen prevalence, neuronal changes, and vascular changes. (From (46))

811

812 **Figure 3:** KEGG pathway analysis of differentially expressed genes in the lungs of non-infected  
813 versus HPAI-infected jungle crows (*Corvus macrorhynchos*). (From (51))

814

815 **Figure 4:** Symptoms of *M. gallisepticum* infection and pathogen load in the conjunctivae of  
816 house finches. A) Symptoms of *M. gallisepticum* infection in naturally infected (Left) and  
817 healthy (Right) wild house finches. (B) Quantification of bacterial load in the conjunctiva of  
818 infected finches from disease-exposed and unexposed populations, 2 weeks post-infection. (From  
819 (63)).

820



821 **Figure 5:** Mass loss in *M. gallisepticum*-infected house finches vs. sham-inoculated controls, and  
822 bacterial load in the conjunctivae of infected finches. (a) Effects of infection with *M.*  
823 *gallisepticum* vs. sham inoculations on mass change (g) between days 0 and 14 post-infection in  
824 finches from disease-exposed (Alabama) and disease-unexposed (Arizona) populations. (b)  
825 Association between bacterial load 14 days post-infection and mass change (g) between days 0  
826 and 14 post-infection in birds from Alabama (open squares) and Arizona (filled diamonds).  
827 (From (86)).

828  
829 **Figure 6:** Pathology of house finches infected with *M. gallisepticum* and originating either from  
830 disease-exposed (Alabama) or disease-unexposed (Arizona) populations. Finches from the  
831 exposed population displayed lower peak eye lesion score (a) and reduced mass loss (b) relative  
832 to finches from unexposed populations, despite similar bacterial load (c). (From (89)).

833  
834 **Figure 7:** Expression of the inflammatory cytokines in the blood of house finches infected with  
835 *M. gallisepticum* and originating either from disease-exposed (Alabama) or disease-unexposed  
836 (Arizona) populations. Expression of the pro-inflammatory cytokine IL-1 $\beta$  was significantly  
837 lower in finches from the exposed population (a), but expression of the anti-inflammatory  
838 cytokine IL-10 was marginally higher in those individuals relative to those from the unexposed  
839 population (b). (From (89)).

840

841 Figure 1


West Nile virus infection	Days post-inoculation				
	1-2	3	4	5	6
<b>AMERICAN CROW (n=3)</b> 	Initiation of WNV replication in blood	Rising viremia titers	Peak viremia $10^{8.2-9.6}$ PFU/ml	Leukocytosis and lymphocytosis  Weak antibody response (% neutralization for 1:20 serum dilution) 41-64%  Hyperthermia	High systemic viral titers mean small intestine: $10^{8.8}$ PFU/ml mean pancreas: $10^{8.8}$ PFU/ml  High viremia $10^{7.3-7.7}$ PFU/ml  Acid-base and electrolyte imbalances Epithelial cell damage Intestinal malabsorption Reduced activity and alertness Diarrhea and dehydration <b>Death</b>
<b>FISH CROW (n=3)</b> 	Initiation of WNV replication in blood	Peak viremia $10^{4.7-6.3}$ PFU/ml	Initial humoral immune response 87-91% neutralization	Leukocytosis and lymphocytosis  Robust humoral immune response 93-100% neutralization  Low viremia $10^{1.7-2.2}$ PFU/ml  <b>Survival</b>	

842

843




844 Figure 2



845

846

847 Figure 3



848

849 Figure 4


850 (a)



851

852

853 (b)



854

855

856

857

858


859 Figure 5

860 (a)


861

862

863




(b)




864 Figure 6



865 (a)



(b)




(c)



874 Figure 7

875 (a)

876



(b)

